What Are Ozempic and Zepbound?
Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes management and cardiovascular risk reduction in adults with heart disease. Zepbound (tirzepatide) is a dual GLP-1 and GIP receptor agonist approved for chronic weight management in adults with obesity or overweight with weight-related conditions. Both are injectable weekly pens, but Zepbound targets weight loss primarily, while Ozempic focuses on diabetes with off-label weight loss use.
How Do They Compare for Weight Loss?
Zepbound shows higher average weight loss than Ozempic in head-to-head trials. In the SURMOUNT-5 trial, Zepbound led to 20.2% mean weight reduction over 72 weeks versus 13.7% for Ozempic at maximum doses (15 mg Zepbound vs. 2.4 mg semaglutide). [1] Real-world data aligns, with Zepbound users losing about 21% body weight at one year compared to 15% for Ozempic users. [2] Both suppress appetite and slow gastric emptying, but Zepbound's dual mechanism enhances fat loss and metabolic effects.
Diabetes Control and Other Uses
Ozempic reduces A1C by 1.5-2% in type 2 diabetes patients and cuts major cardiovascular events by 20% in high-risk groups. [3] Zepbound lowers A1C by up to 2.3% and is FDA-approved for diabetes as Mounjaro, but Zepbound labeling excludes diabetes use. Neither is first-line for diabetes alone due to cost and side effects; Ozempic has stronger heart protection data.
| Aspect | Ozempic (semaglutide) | Zepbound (tirzepatide) |
|--------|-----------------------|------------------------|
| Weight Loss (72 weeks, max dose) | 13-15% | 20-21% [1] |
| A1C Reduction | 1.5-2% [3] | 2-2.3% |
| Primary FDA Approval | Diabetes, CV risk | Weight management |
| Dosing | 0.25-2.4 mg weekly | 2.5-15 mg weekly |
Side Effects and Safety
Both cause gastrointestinal issues: nausea (20-44%), diarrhea (13-30%), vomiting (9-24%). Zepbound has slightly higher rates at equivalent doses but similar dropout rates (around 7%). [1] Ozempic carries a boxed warning for thyroid C-cell tumors in rodents; Zepbound has similar risks. Rare pancreatitis and gallbladder issues occur with both. Zepbound may raise heart rate more (5-6 bpm vs. Ozempic's 2-4 bpm).
Cost and Access
Without insurance, Ozempic costs $900-1,300 monthly; Zepbound $1,000-1,300. Copays vary: $25/month with Eli Lilly/ Novo Nordisk savings cards for eligible patients. Shortages affect both, but compounded versions fill gaps (not FDA-approved). Patents protect both until late 2030s; no generics yet. [4]
Who Makes Them and Availability
Novo Nordisk manufactures Ozempic (U.S. sales $14B in 2023). Eli Lilly makes Zepbound (launched 2023, sales $1.2B). Both require prescriptions; Zepbound pens are single-dose, Ozempic multi-dose.
Sources
[1]: SURMOUNT-5 Trial Results (NEJM)
[2]: Real-World Analysis (JAMA)
[3]: SUSTAIN-6 Trial (NEJM)
[4]: DrugPatentWatch.com - Ozempic Patents | Zepbound Patents